Tamara Zach
Neurology with Special Qualifications in Child Neurology · Phoenix, AZNPI 1962638254
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.9%), food and beverage and education — rather than concentrated in one kind of arrangement. UCB, Inc. accounts for 72.1% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $6,409, more than ten times the $468 reported in 2019.
Across 259 payments — averaging $37.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$7K
- Livanova USA, Inc.$552
- Acadia Pharmaceuticals Inc$418
- Jazz Pharmaceuticals Inc.$233
- Neurelis, Inc.$188
- Greenwich Biosciences, Inc.$183
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$5,15053%
- Travel & lodging$100%
- Food & beverage$4,52346%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 119 | $7,018 |
| Livanova USA, Inc. | 24 | $552 |
| Acadia Pharmaceuticals Inc | 10 | $418 |
| Jazz Pharmaceuticals Inc. | 9 | $233 |
| Neurelis, Inc. | 8 | $188 |
| Greenwich Biosciences, Inc. | 7 | $183 |
| Sunovion Pharmaceuticals Inc. | 17 | $165 |
| AstraZeneca(2 entities) | 5 | $134 |
| Supernus Pharmaceuticals, Inc. | 8 | $111 |
| PTC Therapeutics, Inc. | 2 | $104 |
| Eisai Inc. | 5 | $103 |
| Amneal Pharmaceuticals LLC | 4 | $71 |
| Zogenix Inc. | 3 | $68 |
| Travere Therapeutics, Inc. | 20 | $44 |
| Immedica Pharma US, Inc. | 2 | $41 |
| Aquestive Therapeutics, Inc. | 2 | $41 |
| Biogen | 2 | $38 |
| Sarepta Therapeutics, Inc. | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Mallinckrodt Enterprises LLC | 2 | $30 |
| Aprecia Pharmaceuticals, LLC | 1 | $23 |
| Sanofi | 1 | $22 |
| Genentech USA, Inc. | 1 | $22 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Biomarin Pharmaceutical Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,728 in reported general payments places this provider in the 80th percentile of 49 neurology with special qualifications in child neurology providers in Arizona.
See all neurology with special qualifications in child neurology providers in Arizona →
Other neurology with special qualifications in child neurology in Phoenix
- Angus WilfongPhoenix$348K
- Clara ChowPhoenix$35K
- Saunder BernesPhoenix$27K
- Randa JarrarPhoenix$25K
- Jeffrey BuchhalterPhoenix$19K
- Korwyn WilliamsPhoenix$13K
- Harlori BainsPhoenix$12K
- Javier CardenasPhoenix$6K
- Vinodh NarayananPhoenix$5K
- Richard FryePhoenix$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.